Table 3 Incremental cost-effectiveness analysis
| Â | Â | Cost in RWF (2022) | Inc cost in RWF (2022) | Cost in US$ (2022) | Inc cost in US$ (2022) | Effect QALY | Inc effect | ICER in RWF (2022) | ICER in US$ (2022) |
|---|---|---|---|---|---|---|---|---|---|
Payer Perspective (Age 15–49 years) | Intervention (PD) | 1,824,886 |  | 1,771 |  | 10.01 |  |  |  |
Status quo (HD) | 2,059,354 | -234,468 | 1,999 | -228 | 10.63 | -0.62 | 378,174 | 367 | |
Payer Perspective (Age >  = 50 years) | Intervention (PD) | 1,824,886 |  | 1,771 |  | 5.13 |  |  |  |
Status quo (HD) | 2,059,354 | -234,468 | 1,999 | -228 | 5.4 | -0.27 | 868,399 | 843 |